General Session 3
Session Details
The text of the abstracts will be posted on Monday, November 24.
Moderator
Allison Kurian, Stanford University, Stanford, CA
Moderator
Mariana Chavez Mac Gregor
Presentation numberGS3-01
Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2
Joanne Kotsopoulos, Women's College Hospital, Toronto, ON, Canada
Presentation numberGS3-02
Fertility and ovarian function preservation in premenopausal women with early breast cancer: results from the multicenter prospective PREgnancy and FERtility (PREFER) study
Matteo Lambertini, University of Genova – IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Presentation numberGS3-03
Randomized controlled trial of Young, Empowered & Strong (YES), an mHealth intervention for adolescent and young adult breast cancer survivors
Ann H Partridge, Dana-Farber Cancer Institute, Boston, MA
Presentation numberGS3-04
Effects of Acupuncture vs Sham Acupuncture and Usual Care on Cancer-Related Cognitive Difficulties Among Breast Cancer Survivors: The ENHANCE Randomized Clinical Trial
Jun Mao, Memorial Sloan Kettering Cancer Center, New York, NY
Presentation numberGS3-05
Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial
Eleftherios P Mamounas, AdventHealth Cancer Institute, Orlando, FL
Presentation numberGS3-06
Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer
April C Watt, Peter MacCallum Cancer Centre, Melbourne, Australia
Presentation numberGS3-07
Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0
Laura J Esserman, UCSF, San Francisco, CA
Presentation numberGS3-08
Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial
Komal L Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY
Presentation numberGS3-09
Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor
Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA
Presentation numberGS3-10
Expanding Therapeutic Options in Hormone Receptor Positive Metastatic Breast Cancer
Nicholas Turner, Institute of Cancer Research, London, United Kingdom